Individual Structural Covariance Network Predicts Long-Term Motor Improvement in Parkinson Disease with Subthalamic Nucleus Deep Brain Stimulation

References

1. 1.↵
   1. Mosley PE,
   2. Paliwal S,
   3. Robinson K, et al

   . The structural connectivity of subthalamic deep brain stimulation correlates with impulsivity in Parkinson's disease. Brain 2020;143:2235–54 doi:10.1093/brain/awaa148 pmid:32568370

   CrossRefPubMed
2. 2.↵
   1. Hacker ML,
   2. Turchan M,
   3. Heusinkveld LE, et al

   . Deep brain stimulation in early-stage Parkinson disease: Five-year outcomes. Neurology 2020;95:e393–e401 pmid:32601120

   Abstract/FREE Full Text
3. 3.↵
   1. Cavallieri F,
   2. Fraix V,
   3. Bove F, et al

   . Predictors of long-term outcome of subthalamic stimulation in Parkinson disease. Ann Neurol 2021;89:587–97 doi:10.1002/ana.25994 pmid:33349939

   CrossRefPubMed
4. 4.↵
   1. Barbosa R,
   2. Guedes LC,
   3. Cattoni MB, et al

   . Long-term follow-up of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease: An analysis of survival and disability milestones. Parkinsonism Relat Disord 2023;118:105921 pmid:37976978

   PubMed
5. 5.↵
   1. Shin HW,
   2. Kim MS,
   3. Kim SR, et al

   . Long-term effects of bilateral subthalamic deep brain stimulation on postural instability and gait difficulty in patients with Parkinson's disease. J Mov Disord 2020;13:127–32 doi:10.14802/jmd.19081 pmid:32498496

   CrossRefPubMed
6. 6.↵
   1. Rodriguez-Oroz MC,
   2. Moro E,
   3. Krack P

   . Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 2012;27:1718–28 doi:10.1002/mds.25214 pmid:23208668

   CrossRefPubMed
7. 7.↵
   1. Wolke R,
   2. Becktepe JS,
   3. Paschen S, et al

   . The role of levodopa challenge in predicting the outcome of subthalamic deep brain stimulation. Mov Disord Clin Pract 2023;10:1181–91 doi:10.1002/mdc3.13825 pmid:37635781

   CrossRefPubMed
8. 8.↵
   1. Zheng Z,
   2. Yin Z,
   3. Zhang B, et al

   . levodopa challenge test predicts STN-DBS outcomes in various Parkinson's disease motor subtypes: a more accurate judgment. Neural Plast 2021;2021:4762027 pmid:34721568

   PubMed
9. 9.↵
   1. Piboolnurak P,
   2. Lang AE,
   3. Lozano AM, et al

   . Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord 2007;22:990–97 doi:10.1002/mds.21482 pmid:17443692

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Lin W,
    2. Shi D,
    3. Wang D, et al

    . Can levodopa challenge testing predict the effect of deep brain stimulation? one-year outcomes in a Chinese cohort. Front Aging Neurosci 2021;13:764308 doi:10.3389/fnagi.2021.764308 pmid:34744699

    CrossRefPubMed
11. 11.↵
    1. Geraedts VJ,
    2. van Vugt JPP,
    3. Marinus J, et al

    . Predicting motor outcome and quality of life after subthalamic deep brain stimulation for Parkinson's disease: the role of standard screening measures and wearable-data. J Parkinsons Dis 2023;13:575–88 doi:10.3233/JPD-225101 pmid:37182900

    CrossRefPubMed
12. 12.↵
    1. Chu C,
    2. He N,
    3. Zeljic K, et al

    . Subthalamic and pallidal stimulation in Parkinson's disease induce distinct brain topological reconstruction. Neuroimage 2022;255:119196 doi:10.1016/j.neuroimage.2022.119196 pmid:35413446

    CrossRefPubMed
13. 13.↵
    1. Feigin A,
    2. Kaplitt MG,
    3. Tang C, et al

    . Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:19559–64 doi:10.1073/pnas.0706006104 pmid:18042721

    Abstract/FREE Full Text
14. 14.↵
    1. Logothetis NK

    . What we can do and what we cannot do with fMRI. Nature 2008;453:869–78 doi:10.1038/nature06976 pmid:18548064

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Horn A,
    2. Reich M,
    3. Vorwerk J, et al

    . Connectivity predicts deep brain stimulation outcome in Parkinson disease. Ann Neurol 2017;82:67–78 doi:10.1002/ana.24974 pmid:28586141

    CrossRefPubMed
16. 16.↵
    1. Yang B,
    2. Wang X,
    3. Mo J, et al

    . The altered spontaneous neural activity in patients with Parkinson's disease and its predictive value for the motor improvement of deep brain stimulation. Neuroimage Clin 2023;38:103430 doi:10.1016/j.nicl.2023.103430 pmid:37182459

    CrossRefPubMed
17. 17.↵
    1. Elliott ML,
    2. Knodt AR,
    3. Hariri AR

    . Striving toward translation: strategies for reliable fMRI measurement. Trends Cogn Sci 2021;25:776–87 doi:10.1016/j.tics.2021.05.008 pmid:34134933

    CrossRefPubMed
18. 18.↵
    1. Yin Z,
    2. Bai Y,
    3. Zou L, et al

    . Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease. NPJ Parkinsons Dis 2021;7:47 doi:10.1038/s41531-021-00192-9 pmid:34045471

    CrossRefPubMed
19. 19.↵
    1. Gracien RM,
    2. Maiworm M,
    3. Bruche N, et al

    . How stable is quantitative MRI? - Assessment of intra- and inter-scanner-model reproducibility using identical acquisition sequences and data analysis programs. Neuroimage 2020;207:116364 doi:10.1016/j.neuroimage.2019.116364 pmid:31740340

    CrossRefPubMed
20. 20.↵
    1. Liu Z,
    2. Palaniyappan L,
    3. Wu X, et al

    . Resolving heterogeneity in schizophrenia through a novel systems approach to brain structure: individualized structural covariance network analysis. Mol Psychiatry 2021;26:7719–31 doi:10.1038/s41380-021-01229-4 pmid:34316005

    CrossRefPubMed
21. 21.↵
    1. Lu L,
    2. Xu K,
    3. Shi L, et al

    . Measuring subthalamic nucleus volume of Parkinson's patients and evaluating its relationship with clinical scales at pre- and postdeep brain stimulation treatment: a magnetic resonance imaging study. Biomed Res Int 2021;2021:6646416

    CrossRefPubMed
22. 22.↵
    1. Muthuraman M,
    2. Deuschl G,
    3. Koirala N, et al

    . Effects of DBS in parkinsonian patients depend on the structural integrity of frontal cortex. Sci Rep 2017;7:43571 doi:10.1038/srep43571 pmid:28262813

    CrossRefPubMed
23. 23.↵
    1. Chen Y,
    2. Zhu G,
    3. Liu Y, et al

    . Predict initial subthalamic nucleus stimulation outcome in Parkinson's disease with brain morphology. CNS Neurosci Ther 2022;28:667–76 doi:10.1111/cns.13797 pmid:35049150

    CrossRefPubMed
24. 24.↵
    1. Ping L,
    2. Sun S,
    3. Zhou C

    , DIRECT Consortium, et al. Altered topology of individual brain structural covariance networks in major depressive disorder. Psychol Med 20231–12 pmid:37698447

    PubMed
25. 25.↵
    1. Li R,
    2. Zou T,
    3. Wang X, et al

    . Basal ganglia atrophy-associated causal structural network degeneration in Parkinson's disease. Hum Brain Mapp 2022;43:1145–56 doi:10.1002/hbm.25715 pmid:34792836

    CrossRefPubMed
26. 26.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
27. 27.↵
    1. Jost ST,
    2. Kaldenbach MA,
    3. Antonini A

    , International Parkinson and Movement Disorders Society Non-Motor Parkinson Disease Study Group, et al. Levodopa dose equivalency in Parkinson's disease: updated systematic review and proposals. Mov Disord 2023;38:1236–52 doi:10.1002/mds.29410 pmid:37147135

    CrossRefPubMed
28. 28.↵
    1. Goetz CG,
    2. Tilley BC,
    3. Shaftman SR

    , Movement Disorder Society UPDRS Revision Task Force, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–70 doi:10.1002/mds.22340 pmid:19025984

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Schrag A,
    2. Sampaio C,
    3. Counsell N, et al

    . Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200–07 doi:10.1002/mds.20914 pmid:16673410

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Liu X,
    2. Wang Y,
    3. Ji H, et al

    . Personalized characterization of diseases using sample-specific networks. Nucleic Acids Res 2016;44:e164 doi:10.1093/nar/gkw772 pmid:27596597

    CrossRefPubMed
31. 31.↵
    1. Jenkinson M,
    2. Bannister P,
    3. Brady M, et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 doi:10.1006/nimg.2002.1132 pmid:12377157

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Pedregosa F,
    2. Varoquaux G,
    3. Gramfort A, et al

    . Scikit-learn: machine learning in Python. Journal of Machine Learning Research 2011;12:2825–30
33. 33.↵
    1. Zaidel A,
    2. Bergman H,
    3. Ritov Y, et al

    . Levodopa and subthalamic deep brain stimulation responses are not congruent. Mov Disord 2010;25:2379–86 doi:10.1002/mds.23294 pmid:20824733

    CrossRefPubMed
34. 34.↵
    1. Dembek TA,
    2. Roediger J,
    3. Horn A, et al

    . Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease. Ann Neurol 2019;86:527–38 doi:10.1002/ana.25567 pmid:31376171

    CrossRefPubMed
35. 35.↵
    1. Fasano A,
    2. Romito LM,
    3. Daniele A, et al

    . Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010;133:2664–76 doi:10.1093/brain/awq221 pmid:20802207

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Lozano AM,
    2. Lipsman N,
    3. Bergman H, et al

    . Deep brain stimulation: current challenges and future directions. Nat Rev Neurol 2019;15:148–60 doi:10.1038/s41582-018-0128-2 pmid:30683913

    CrossRefPubMed
37. 37.↵
    1. Shang S,
    2. Zhang H,
    3. Feng Y, et al

    . Region-specific neurovascular decoupling associated with cognitive decline in Parkinson's disease. Front Aging Neurosci 2021;13:770528 doi:10.3389/fnagi.2021.770528 pmid:34867297

    CrossRefPubMed
38. 38.↵
    1. Deng X,
    2. Liu Z,
    3. Kang Q, et al

    . Cortical structural connectivity alterations and potential pathogenesis in mid-stage sporadic Parkinson's disease. Front Aging Neurosci 2021;13:650371 doi:10.3389/fnagi.2021.650371 pmid:34135748

    CrossRefPubMed
39. 39.↵
    1. Yan S,
    2. Lu J,
    3. Li Y, et al

    . Impaired topological properties of cortical morphological brain networks correlate with motor symptoms in Parkinson's disease. J Neuroradiol 2023 doi:10.1016/j.neurad.2023.09.007

    CrossRef
40. 40.↵
    1. Hacker ML,
    2. Rajamani N,
    3. Neudorfer C, et al

    . Connectivity profile for subthalamic nucleus deep brain stimulation in early stage Parkinson disease. Ann Neurol 2023;94:271–84 pmid:37177857

    CrossRefPubMed
41. 41.↵
    1. David FJ,
    2. Goelz LC,
    3. Tangonan RZ, et al

    . Bilateral deep brain stimulation of the subthalamic nucleus increases pointing error during memory-guided sequential reaching. Exp Brain Res 2018;236:1053–65 doi:10.1007/s00221-018-5197-3 pmid:29427240

    CrossRefPubMed
42. 42.↵
    1. Neumann WJ,
    2. Schroll H,
    3. de Almeida Marcelino AL, et al

    . Functional segregation of basal ganglia pathways in Parkinson's disease. Brain 2018;141:2655–69 pmid:30084974

    CrossRefPubMed
43. 43.↵
    1. Irmady K,
    2. Hale CR,
    3. Qadri R, et al

    . Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson's disease. Nat Commun 2023;14:3956 doi:10.1038/s41467-023-39652-6 pmid:37407548

    CrossRefPubMed
44. 44.↵
    1. Castrioto A,
    2. Lozano AM,
    3. Poon YY, et al

    . Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550–56 doi:10.1001/archneurol.2011.182 pmid:21825213

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Rabel C,
    2. Le Goff F,
    3. Lefaucheur R, et al

    . Subjective perceived motor improvement after acute levodopa challenge in Parkinson's disease. J Parkinsons Dis 2016;6:779–85 doi:10.3233/JPD-160906 pmid:27662330

    Abstract/FREE Full Text
46. 46.↵
    1. Jahanshahi M,
    2. Leimbach F,
    3. Rawji V

    . Short and long-term cognitive effects of subthalamic deep brain stimulation in Parkinson's disease and identification of relevant factors. J Parkinsons Dis 2022;12:2191–209 doi:10.3233/JPD-223446 pmid:36155529

    Abstract/FREE Full Text
47. 47.↵
    1. Guimaraes TG,
    2. Cury RG

    . Troubleshooting gait problems in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. J Parkinsons Dis 2022;12:737–41 doi:10.3233/JPD-212771 pmid:34924400

    CrossRefPubMed